Related Experiment Video
Updated: Jun 1, 2025
09:23
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
16.7K
Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From
Sarah-Eve Lemay1, Mónica S Montesinos2, Yann Grobs1
1Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).
Circulation
|January 20, 2025
Summary
Targeting integrin α5β1 offers a promising new treatment for pulmonary arterial hypertension (PAH). Inhibiting this molecule effectively reduces vascular remodeling and improves heart function in preclinical PAH models.
Area of Science:
- Cardiovascular Research
- Integrin Biology
- Pulmonary Hypertension Pathophysiology
Background:
- Pulmonary arterial hypertension (PAH) involves pulmonary artery remodeling and leads to right ventricular failure.
- Current PAH treatments have limited efficacy, highlighting the need for novel therapeutic targets.
- Integrins are implicated in vascular remodeling, but their specific role in PAH is not well understood.
Purpose of the Study:
- To investigate the role of integrin α5β1 in pulmonary arterial hypertension (PAH) pathogenesis.
- To evaluate the therapeutic potential of α5β1 integrin inhibition in preclinical PAH models.
Main Methods:
- Assessed α5β1 integrin expression in pulmonary arteries (PAs) from PAH patients and controls.
- Utilized RNA sequencing to identify gene networks regulated by α5β1 inhibition.
- Evaluated therapeutic efficacy of α5β1 blockade using small molecule inhibitors and antibodies in rat PAH models.
- Compared efficacy against standard-of-care and sotatercept using hemodynamic, echocardiographic, and histological assessments.
- Performed ex vivo studies on human precision-cut lung slices.
Main Results:
- Integrin α5β1 is upregulated in PAs of PAH patients and animal models.
- α5β1 blockade downregulated FOXM1-regulated genes, inhibiting proliferation and promoting apoptosis resistance in PAH cells.
- α5β1 integrin inhibition attenuated pulmonary vascular remodeling, improved hemodynamics, and enhanced right ventricular function.
- Therapeutic efficacy matched or exceeded standard-of-care and sotatercept in preclinical models.
- Ex vivo studies confirmed reversal of advanced remodeling in human lung slices.
Conclusions:
- Integrin α5β1 is a key driver of pulmonary arterial hypertension (PAH) pathology.
- Inhibition of α5β1 integrin represents a novel, safe, and effective therapeutic strategy for PAH.
- Further research into α5β1 integrin as a drug target for PAH is warranted.
Keywords:
extracellular matrixheart ventricleshypertension, pulmonaryintegrinsmodels, animalvascular remodelingMore Related Videos
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
132
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
132
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
133
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
133
01:17Intracellular Signaling Affects Focal Adhesions
2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.5K
01:30Pulmonary Hypertension: Classification and Pathogenesis
149
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
149
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129